Targeting CD38 in Neoplasms and Non-Cancer Diseases
Wojciech Szlasa(Wroclaw Medical University), Ewa Barg(Wroclaw Medical University), Katarzyna Rakoczy(Wroclaw Medical University), Natalia Sauer(Wroclaw Medical University), Jakub Czarny(Poznan University of Medical Sciences), Jakub Stecko(Wroclaw Medical University), Maksymilian Kołodziej(Poznan University of Medical Sciences), Maciej Kaźmierczak(Silesian University of Technology), Natalia Szymańska(Wroclaw Medical University)
Cited by 31
Related Papers
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
|Blood Advances|2020|109
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
|Journal of Clinical Oncology|2022|93
Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR
|International Journal of Oncology|2017|80